



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On

20 Sept. 2001

TOWNSEND and TOWNSEND and CREW LLP

By:

Malinda D. Dwyer

Attorney Docket No.: 015280-315100US
Client Ref. No.: E-094-97/0

PATENT

RECEIVED
SEP 27 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CHANDRASEKHARAPPA *et al.*

Application No.: 09/380,337

Filed: March 6, 2000

For: *MEN1*, THE GENE ASSOCIATED
WITH MULTIPLE ENDOCRINE
NEOPLASIA TYPE 1, MENIN
POLYPEPTIDES AND USES THEREOF

Examiner: Hunt, Jennifer

Art Unit: 1642

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Examiner's Communication mailed June 20, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.